Samina T Syed1, Lisa K Sharp1,2,3, Yoonsang Kim2, Adam Jentleson2, Claudia M Lora1, Daniel R Touchette3, Michael L Berbaum2, Katie J Suda3,4, Ben S Gerber1,2,5. 1. Department of Medicine, University of Illinois at Chicago, Chicago, Illinois. 2. Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, Illinois. 3. Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois. 4. Center of Innovation for Complex Chronic Healthcare, Hines VA Medical Center, Hines, Illinois. 5. Center of Innovation for Complex Chronic Healthcare, Jesse Brown VA Medical Center, Chicago, Illinois.
Abstract
STUDY OBJECTIVE: To determine whether a relationship exists between medication adherence to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and distance to dispensing pharmacies and prescribers among an urban public aid population with diabetes mellitus. DESIGN: Retrospective cohort study using claims data. DATA SOURCE: Illinois Department of Healthcare and Family Services database. PATIENTS: A total of 6532 patients aged 18-64 years with diabetes who had at least one prescription fill for an ACEI or ARB and had continuous Medicaid coverage in the greater Chicago area in 2009. MEASUREMENTS AND MAIN RESULTS: We assessed medication adherence, defined as proportion of days covered (PDC) of 0.8 or higher, to ACEIs and ARBs and its association with distances between patients and their pharmacies and prescribers. Of the 6532 patients included in the analyses, 2930 (45%) had PDC levels of 0.8 or higher. No significant differences were observed between patients who were adherent versus those who were nonadherent in distance to pharmacy (median 1.39 vs 1.35 miles, p=0.15) or distance to prescriber (median 4.39 vs 4.48 miles, p=0.80). In a multivariate regression model including age, sex, race/ethnicity, number of pharmacies, number of prescribers, distance to pharmacy, and distance to prescriber, a greater number of prescribers was associated with higher adherence (two prescribers vs one prescriber: odds ratio [OR] 1.396, 95% confidence interval [CI] 1.233-1.580; three or more prescribers vs one prescriber: OR 2.208, 95% CI 1.787-2.727). CONCLUSION: ACEI or ARB adherence was not associated with distances to pharmacies and prescribers.
STUDY OBJECTIVE: To determine whether a relationship exists between medication adherence to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and distance to dispensing pharmacies and prescribers among an urban public aid population with diabetes mellitus. DESIGN: Retrospective cohort study using claims data. DATA SOURCE: Illinois Department of Healthcare and Family Services database. PATIENTS: A total of 6532 patients aged 18-64 years with diabetes who had at least one prescription fill for an ACEI or ARB and had continuous Medicaid coverage in the greater Chicago area in 2009. MEASUREMENTS AND MAIN RESULTS: We assessed medication adherence, defined as proportion of days covered (PDC) of 0.8 or higher, to ACEIs and ARBs and its association with distances between patients and their pharmacies and prescribers. Of the 6532 patients included in the analyses, 2930 (45%) had PDC levels of 0.8 or higher. No significant differences were observed between patients who were adherent versus those who were nonadherent in distance to pharmacy (median 1.39 vs 1.35 miles, p=0.15) or distance to prescriber (median 4.39 vs 4.48 miles, p=0.80). In a multivariate regression model including age, sex, race/ethnicity, number of pharmacies, number of prescribers, distance to pharmacy, and distance to prescriber, a greater number of prescribers was associated with higher adherence (two prescribers vs one prescriber: odds ratio [OR] 1.396, 95% confidence interval [CI] 1.233-1.580; three or more prescribers vs one prescriber: OR 2.208, 95% CI 1.787-2.727). CONCLUSION: ACEI or ARB adherence was not associated with distances to pharmacies and prescribers.
Authors: M Alan Brookhart; Amanda R Patrick; Sebastian Schneeweiss; Jerry Avorn; Colin Dormuth; William Shrank; Boris L G van Wijk; Suzanne M Cadarette; Claire F Canning; Daniel H Solomon Journal: Arch Intern Med Date: 2007-04-23
Authors: Matthew L Maciejewski; Benjamin J Powers; Linda L Sanders; Joel F Farley; Richard A Hansen; Betsy Sleath; Corrine I Voils Journal: J Gen Intern Med Date: 2014-01-10 Impact factor: 5.128
Authors: Niteesh K Choudhry; Michael A Fischer; Jerry Avorn; Joshua N Liberman; Sebastian Schneeweiss; Juliana Pakes; Troyen A Brennan; William H Shrank Journal: Arch Intern Med Date: 2011-05-09
Authors: Wolfgang C Winkelmayer; Michael A Fischer; Sebastian Schneeweiss; Philip S Wang; Raisa Levin; Jerry Avorn Journal: Am J Kidney Dis Date: 2005-12 Impact factor: 8.860
Authors: Richard A Hansen; Corrine I Voils; Joel F Farley; Benjamin J Powers; Linda L Sanders; Betsy Sleath; Matthew L Maciejewski Journal: Ann Pharmacother Date: 2014-12-30 Impact factor: 3.154
Authors: Yuhong Zhou; Kirsten M M Beyer; Purushottam W Laud; Aaron N Winn; Liliana E Pezzin; Ann B Nattinger; Joan Neuner Journal: J Pharm Health Serv Res Date: 2021-01-16
Authors: James E Bailey; Cathy Gurgol; Eric Pan; Shirilyn Njie; Susan Emmett; Justin Gatwood; Lynne Gauthier; Lisa G Rosas; Shannon M Kearney; Samantha Kleindienst Robler; Raymona H Lawrence; Karen L Margolis; Ifeyinwa Osunkwo; Denise Wilfley; Vallabh O Shah Journal: J Med Internet Res Date: 2021-12-07 Impact factor: 5.428